| TYSABRI® (Natalizumab) is a treatment approved for relapsing forms of Multiple Sclerosis in the United States and relapsing-remitting MS in the European Union. It is a recombinant humanised monoclonal antibody produced in murine myeloma cells. The specific mechanism(s) by which TYSABRI® exerts its effects in multiple sclerosis have not been fully defined. However, Pharmacodynamic data has shown that TYSABRI® administration increases the number of circulating leukocytes (including lymphocytes, monocytes, basophils, and eosinophils) due to inhibition of transmigration out of the vascular space. TYSABRI® does not affect the number of circulating neutrophils. According to data that have been published in the New England Journal of Medicine, after two years, Tysabri® treatment led to a 68% relative reduction (p<0.001) in the annualised relapse rate compared to placebo and reduced the relative risk of disability progression by 42-54% (p<0.001). In addition to the United States and European Union, Tysabri® is also approved for MS in Switzerland, Canada, Australia, New Zealand and Israel. Tysabri® was discovered by Elan and is co-developed with Biogen Idec. Source: Biogen Idec. |
To aid those who may have been prescribed Tysabri® or those thinking of asking their Neurologist to prescribe Tysabri®.